NCT00907348Unknown2 期
Prospective Multicenter Dose Finding Phase II Pilot Trial to Evaluate Efficacy and Safety of Treatment With Lenalidomide Plus R-CHOP21 (LR-CHOP21) for Elderly Patients With Untreated Diffuse Large B Cell Lymphoma (DLBCL)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 49
- 试验地点
- 18
- 主要终点
- Evaluation of adverse events according with Common Terminology Criteria for Adverse events (CTCAE)
研究概览
简要总结
This is a prospective multicenter phase II pilot trial designed with the purpose of dose finding to evaluate the efficacy and safety of treatment with Lenalidomide plus R-CHOP21 (LR-CHOP21) for elderly patients with untreated Diffuse Large B Cell Lymphoma (DLBCL).
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 60 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Understand and voluntarily sign an informed consent form
- •Able to adhere to the study visit schedule and other protocol requirements
- •Histologic subtypes as follows:
- •CD20 positive Diffuse large B-Cell lymphoma
- •CD20 positive Follicular grade IIIb
- •Untreated patients. In patients with bulky mass or systemic symptoms or compressive disease or rapidly progressive adenopathies a pre-study treatment is allowed with steroids and/or a single dose of Vincristine 1.4 mg/mq (max 2) in the seven days prior the start of the study treatment
- •Measurable and/or evaluable disease
- •Ann Arbor stage II, III, IV
- •International Prognostic Index at low-intermediate, intermediate-high, high risk (2/3/4-5)
- •Adequate haematological counts: ANC > 1.5 x 109/L and platelet count > 75 x 109/L unless due to bone marrow involvement
- •Conjugated bilirubin up to 2 x UNL
- •Alkaline phosphatase and transaminases up to 2 x UNL
- •Creatinine clearance > 50 ml/min
- •HIV negativity
- •HCV negativity
- •HBV negativity or patients with HBVcAb +, HbsAg -, HBs Ab+/- with HBV-DNA negative
- •Cardiac ejection fraction (MUGA scan or echocardiography) > 45%
- •Non peripheral neuropathy or CNS disease. Non testicular Lymphoma
- •Life expectancy > 6 months
- •Performance status < 2 according to ECOG scale
- •Comprehensive geriatric assessment (CGA) as outlined in Appendix 15 showing absence of any impairment in activity of daily living (ADL), of any condition defining a geriatric syndrome, and of any grade 4 comorbidity or of more than three grade 3 comorbidities according to CIRS-G scale
- •Disease free of prior malignancies for ≥ 3 years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma "in situ" of the cervix or breast
- •Females of childbearing potential (FCBP) must agree to use two reliable forms of contraception simultaneously or to practice complete abstinence from heterosexual intercourse during the following time periods related to this study: for at least 28 days before starting study drug;while participating in the study; for at least 28 days after discontinuation from the study
- •The two methods of reliable contraception must include one highly effective method (i.e., intrauterine device (IUD), hormonal [birth control pills, injections, or implants], tubal ligation, partner's vasectomy) and one additional effective (barrier) method (i.e., latex condom, diaphragm, cervical cap)
- •FCBP must be referred to a qualified provider of contraceptive methods if needed
排除标准
- •Lymphoblastic Lymphoma
- •Burkitt Lymphoma
- •Non Hodgkin lymphoma CD 20 negative
- •Mantle Cell Lymphoma
- •Follicular Non Hodgkin Lymphoma grade I-II-IIIa
- •Primitive mediastinal diffuse large B cell lymphoma with only mediastinal involvement
- •International Prognostic Index at low risk (1)
- •Has known or suspected hypersensitivity or intolerance to Rituximab
- •History of evolutive malignancy within the last 3 years other than squamous cell and basal cell carcinoma of the skin or carcinoma in situ of the cervix or breast
- •Extensive radiation therapy, systemic chemotherapy, or other antineoplastic therapy before enrollment within 3 years before the start of treatment
- •Exposure to Rituximab prior to study entry
- •Have received an experimental drug or used an experimental medical device within 4 weeks before the planned start of treatment. Concurrent participation in non-treatment studies is allowed, if it will not interfere with participation in this study
- •CNS disease (meningeal and/or brain involvement by lymphoma) or Testicular involvement
- •DVT in the last year
- •History of clinically relevant liver or renal insufficiency; significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, rheumatologic, hematologic, psychiatric, or metabolic disturbances
- •Uncontrolled diabetes (if receiving antidiabetic agents, subjects must be on a stable dose for at least 3 months before first dose of study drug
- •Uncontrolled or severe cardiovascular disease including myocardial infarction within 6 months of enrollment, New York Heart Association (NYHA) Class III or IV heart failure (Attachment 5, NYHA Classification of Cardiac Disease), uncontrolled angina, clinically significant pericardial disease, or cardiac amyloidosis
- •Creatinine clearance < 50 ml/min
- •Presence of major neurological disorders
- •HIV positivity
- •HBV positivity with the exception of patients with HBVcAb +, HbsAg -, HBs Ab+/- with HBV-DNA negative
- •HCV positivity
- •Active opportunistic infection
- •Comprehensive geriatric assessment (CGA) as outlined in Appendix 15 showing presence of any impairment in activity of daily living (ADL), of any condition defining a geriatric syndrome, and of any grade 4 comorbidity or of more than three grade 3 comorbidities according to CIRS-G scale
- •Any other co-existing medical or psychological condition that would preclude participation in the study or compromise ability to give informed consent
研究组 & 干预措施
Cohorts 1 - 2 - 3 - 4
Experimental
Chemiotherapy
干预措施: LR-CHOP21 (Drug)
结局指标
主要结局
Evaluation of adverse events according with Common Terminology Criteria for Adverse events (CTCAE)
时间窗: 2 years
次要结局
- Overall Response Rate (ORR)(4 years)
研究者
研究点 (18)
Loading locations...
相似试验
暂停
2 期
Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Relapsing Forms of Multiple SclerosisRelapsing Forms of Multiple SclerosisNCT04909502Emerald Health Pharmaceuticals50
已完成
2 期
Phase II Trial Designed to Determine Efficacy and Safety of Bendamustine+Dexamethasone+Thalidomide in R/R MMMultiple MyelomaNCT01526694Azienda Ospedaliera di Bolzano30
已完成
2 期
Medytoxin® Treatment in Patients With Benign Masseteric HypertrophyHypertrophy of Masseter MuscleNCT02292472Medy-Tox69
已完成
1 期
A Trial to Determine Radiation Exposure to Organs and Assess the Safety of CARDIOLITE® in Pediatric SubjectsKawasaki DiseaseNCT00162045Lantheus Medical Imaging79
已完成
2 期
A Dose-Finding Study of MM-120 (LSD D-Tartrate) for the Treatment of Anxiety SymptomsAnxiety GeneralizedNCT05407064Mind Medicine, Inc.198